Recent performance snapshot

Alignment Healthcare (ALHC) has seen mixed share performance recently, with a 2.7% gain over the past day, a 1.9% decline over the past week, a 15.5% decline over the past month, and a 4.7% gain over the past 3 months.

Stepping back, Alignment Healthcare’s short term share price pressure contrasts with a much stronger backdrop, with a 1 year total shareholder return of 52.96% and a 3 year total shareholder return around 2.5x the starting point. This hints at shifting expectations around its growth prospects and risk profile.

If this Medicare focused story has your attention and you want to see what else is out there, take a look at our screener of 30 healthcare AI stocks as potential next ideas.

With Alignment Healthcare trading at US$20.13 against an average analyst price target of about US$25.17 and carrying a relatively low value score of 4, is the current pullback a genuine opening, or is the market already pricing in future growth?

Most Popular Narrative: 4.3% Undervalued

Based on the most followed narrative, Alignment Healthcare’s fair value of $21.04 sits modestly above the last close at $20.13, framing a slight valuation gap that hinges on future execution.

Alignment's robust, technology-enabled care model and investments in administrative automation, workflow standardization, and digital health platforms position the company to significantly lower SG&A expenses and improve scalability, likely powering both margin expansion and earnings growth over the next several years.

Curious what kind of revenue ramp, margin lift, and earnings profile need to line up for that fair value to make sense? The core narrative leans on faster top line growth than the broader US market, a swing from losses to profitability, and a richer earnings multiple than many healthcare names. Want to see exactly how those pieces are stitched together into that $21.04 number and why the discount rate really matters here?

Result: Fair Value of $21.04 (UNDERVALUED)

However, this hinges on Medicare Advantage policy staying relatively supportive and on competition not pushing up member acquisition costs faster than expected.

Another angle on value

That slight 4.3% discount to the $21.04 fair value sits awkwardly beside our DCF estimate, which points to a fair value of about $18.60. In that view, Alignment Healthcare at $20.13 screens as overvalued, not undervalued. Which narrative do you find more convincing?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Alignment Healthcare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this mix of upside potential and concern sit right with you, or does it feel off? Is it worth forming a view now by looking closely at 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Alignment Healthcare has sharpened your thinking, do not stop here. The wider market holds plenty of other stories that could fit your portfolio goals.

• Target potential mispricings by checking companies that screen as 53 high quality undervalued stocks based on solid fundamentals and conservative assumptions.
• Prioritise resilience by reviewing 80 resilient stocks with low risk scores that aim to keep overall portfolio volatility in check.
• Hunt for off the radar opportunities with our screener containing 23 high quality undiscovered gems before attention and liquidity potentially pick up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.